Ready to join a team committed to moving gene therapies into the clinical and commercial settings for patients and families devastated by rare neurological genetic diseases? AveXis is advancing cutting-edge science to treat rare and life-threatening genetic diseases starting with our clinical-stage, proprietary gene therapy candidate, AVXS-101. We are in the midst of an incredible journey, and are looking for passionate individuals to join us on this important mission.
AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.
The Senior Director will work with the head of Global Medical Affairs (GMA), all centers of excellence within GMA and regional teams and their senior-level and executive management to ensure that some recently identified initiatives to strengthen the Global Medical Affairs organization, in preparation for launch, managing the lifecycle of AVXS-101 and to advance the scientific exchange regarding the pipeline and platform, are planned, executed, and socialized well. The current processes overall, operational rhythm, and optimal communication will be general themes to be addressed.
The Senior Director will act as owner of “Medical Excellence”, be responsible for executing these initiatives, and measure and report impact, spanning this launch year, 2019 and several years beyond as new products leveraging the AveXis gene therapy platform. The most pressing of these processes is a global process in place to review grants, represent them fairly, and allocate funds in accordance to AveXis’ strategic priorities. This individual will ensure integration of grant management and other data systems and associated processes across other AveXis departments and regions (e.g., EMEA) and help drive the strategic direction along with other functional partners and execute on the agreed-to strategy.
They will also own related processes as well as operations regarding all Managed Access Programs (Compassionate Use, Early Access, etc.). This position will also be working cross-functionally to streamline standard operating procedures (SOPs) across the corporation and incorporate requisite Medical considerations.
The level of this position will be based on the final candidate’s qualifications.
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
AveXis is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity, national origin, genetics, disability, age, sexual orientation or veteran status.